News Releases

Allon Therapeutics presents at European BioSquare partnering conference

VANCOUVER, April 14 /CNW/ - Allon Therapeutics Inc. (TSX-V: "NPC"), The Neuro Protection Company(TM), is today presenting an update of the company's clinical development program and overall business strategy at Biosquare 2005, a life sciences partnering conference in Lyon, France. Gordon McCaule... Continue reading →

Allon reports 2004 audited operating results

VANCOUVER, April 12 /CNW/ - Allon Therapeutics Inc. (TSX-V: "NPC"), The Neuro Protection Company(TM), reported today its 2004 audited operating results. The Company met all of its publicly stated milestones in 2004 and subsequently has met all of its year-to-date 2005 milestones. Financials For... Continue reading →

Allon CSO presents pre-clinical data to Alzheimer's/Parkinson's conference in Sorrento, Italy

VANCOUVER, March 14 /CNW/ - Allon Therapeutics Inc. (TSX-V: "NPC"), The Neuro Protection Company(TM), has presented pre-clinical data to an international conference on Alzheimer's and Parkinson's disease that helps explain how the company's proprietary lead compound AL-108 protects brain cells fr... Continue reading →

Allon Therapeutics compounds show potential to treat eye disease

VANCOUVER, March 8 /CNW/ - Two proprietary compounds of Allon Therapeutics Inc. (TSX-V: "NPC"), "The Neuro Protection Company", have the potential to become new treatments for diseases of the optic nerve and retina -- including glaucoma, the second most common cause of blindness in the United Sta... Continue reading →

Allon completes dosing in Phase Ia human clinical trials for lead product

VANCOUVER , March 2 /CNW/ - Allon Therapeutics Inc. (TSX-V: "NPC"), "The Neuro Protection Company", announced today it has completed dosing for its Phase Ia human clinical trial evaluating the company's lead product AL-108 as a treatment for Alzheimer's disease. Gordon McCauley, President of All... Continue reading →

← Older posts Newer posts →